| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
47.61(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,511 |
191,640 |
263,030 |
1,586,782 |
| Total Sell Value |
$37,495 |
$144,338 |
$351,679 |
$10,312,191 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
38 |
59 |
108 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brenner Malcolm |
Director |
– • – |
2021-03-03 |
4 |
AS |
$36.91 |
$679,950 |
I/I |
(17,915) |
916,352 |
|
-51% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-03-02 |
4 |
AS |
$37.93 |
$19,420 |
D/D |
(512) |
472,522 |
|
-50% |
|
| Vera Juan |
Director |
– • – |
2021-03-02 |
4 |
AS |
$37.28 |
$571,396 |
D/D |
(14,994) |
2,355,916 |
|
-50% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-02 |
4 |
AS |
$37.35 |
$482,388 |
I/I |
(12,658) |
934,267 |
|
-50% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-03-01 |
4 |
AS |
$38.62 |
$230,034 |
D/D |
(5,932) |
488,230 |
|
-49% |
|
| Vera Juan |
Director |
– • – |
2021-03-01 |
4 |
AS |
$38.28 |
$1,267,778 |
D/D |
(32,854) |
2,370,910 |
|
-49% |
|
| Miller Edward |
General Counsel |
• – – |
2021-03-01 |
4 |
AS |
$38.58 |
$232,699 |
I/I |
(6,000) |
192,811 |
|
-49% |
|
| Brenner Malcolm |
Director |
– • – |
2021-03-01 |
4 |
AS |
$38.39 |
$838,227 |
I/I |
(21,694) |
946,925 |
|
-49% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-03-01 |
4 |
AS |
$38.46 |
$368,329 |
I/I |
(9,518) |
2,462,167 |
|
-49% |
|
| Brenner Malcolm |
Director |
– • – |
2021-02-23 |
4 |
AS |
$38.75 |
$335,036 |
I/I |
(8,489) |
968,619 |
|
-49% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-23 |
4 |
AS |
$39.18 |
$83,783 |
D/D |
(2,118) |
494,162 |
|
-49% |
|
| Vera Juan |
Director |
– • – |
2021-02-23 |
4 |
AS |
$38.33 |
$348,684 |
D/D |
(8,850) |
2,403,764 |
|
-49% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-23 |
4 |
AS |
$38.83 |
$165,876 |
I/I |
(4,199) |
2,471,685 |
|
-49% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-02-22 |
4 |
AS |
$43.14 |
$34,509 |
D/D |
(800) |
64,765 |
|
-50% |
|
| Brenner Malcolm |
Director |
– • – |
2021-02-22 |
4 |
AS |
$41.58 |
$486,246 |
I/I |
(11,423) |
977,108 |
|
-50% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-22 |
4 |
AS |
$41.53 |
$119,118 |
D/D |
(2,800) |
496,280 |
|
-50% |
|
| Vera Juan |
Director |
– • – |
2021-02-22 |
4 |
AS |
$41.58 |
$609,614 |
D/D |
(14,321) |
2,412,614 |
|
-50% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-22 |
4 |
AS |
$41.54 |
$242,880 |
I/I |
(5,706) |
2,475,884 |
|
-50% |
|
| Brenner Malcolm |
Director |
– • – |
2021-02-19 |
4 |
AS |
$41.78 |
$500,935 |
I/I |
(11,990) |
988,531 |
|
-53% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-19 |
4 |
AS |
$41.71 |
$173,720 |
D/D |
(4,165) |
499,080 |
|
-53% |
|
| Vera Juan |
Director |
– • – |
2021-02-19 |
4 |
AS |
$41.79 |
$553,011 |
D/D |
(13,233) |
2,426,935 |
|
-53% |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2021-02-19 |
4 |
AS |
$41.75 |
$314,868 |
I/I |
(7,541) |
2,481,590 |
|
-53% |
|
| Bornstein Jeffrey S |
Director |
– • – |
2021-02-18 |
4 |
S |
$40.39 |
$832,119 |
I/I |
(20,583) |
0 |
|
53% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2021-02-18 |
4 |
AS |
$39.83 |
$84,787 |
D/D |
(2,085) |
503,245 |
|
-53% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2021-02-18 |
4 |
AS |
$39.36 |
$29,724 |
D/D |
(741) |
65,565 |
|
-53% |
|
288 Records found
|
|
Page 9 of 12 |
|
|
0.02 (2.93%) 
